NCT04806243

Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）

A Phase II, Second-line, Single-arm Clinical Trial of Carelizumab Combined With Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 69 (estimated)
• Sponsor: Nanfang Hospital, Southern Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To investigate the efficacy and safety of carelizumab combined with regorafenib in second-line treatment for patients with primary hepatocellular carcinoma.

Detailed description

Currently, there is little experience in the application of targeted drugs combined with immunotherapy. Through this study, we hope to explore the optimal population for the use of carelizumab combined with regorafenib in the second-line treatment of hepatocellular carcinoma (HCC), as well as the efficacy and safety. This research is a single-center trials phase II second-line, single arm, explore the clinical outcome of treatment.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Regorafenib Pill&Camrelizumab	Regorafenib，80 mg，QD，Q3w Camrelizumab，200 mg，IV，Q3w

Timeline

• Start date: 2021-05-06
• Primary completion: 2022-01-01
• Completion: 2022-01-01
• First posted: 2021-03-19
• Last updated: 2021-06-30

Locations

1 site across 1 country: China